Q-omics provides the consensus-scored SRP9P1 profile across patient tissues and cancer cell-line models. SRP9P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SRP9P1 is differentially expressed in 13, with the highest sampling consensus in BRCA. Additionally, SRP9P1 RNA expression shows 18,490 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BRCA, and ACC as cancer lineages where SRP9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRP9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRP9P1 survival associations across molecular data types. SRP9P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRP9P1 RNA expression–survival associations across cancer types. High SRP9P1 expression shows unfavorable associations in STAD, DLBC, LGG and ACC, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SRP9P1 RNA expression.
This table summarizes SRP9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SRP9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRP9P1 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUAD, LIHC, COAD and LUSC. The BRCA box plot shows higher SRP9P1 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with SRP9P1 in patient tissues and cancer cell lines. In patient samples, SRP9P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
